Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis by Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates

Get full text

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model by Philipp Schwabl, Eva Hambruch, Grant R. Budas, Paul Supper, Michael Burnet, John T. Liles, Manfred Birkel, Ksenia Brusilovskaya, Philipp Königshofer, Markus Peck-Radosavljevic, William J. Watkins, Michael Trauner, David G. Breckenridge, Claus Kremoser, Thomas Reiberger

Get full text

Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver Fibrosis by Ross Dobie, John R. Wilson-Kanamori, Beth E.P. Henderson, James R. Smith, Kylie P. Matchett, Jordan R. Portman, Karolina Wallenborg, Simone Picelli, Anna Zagorska, Swetha V. Pendem, Thomas E. Hudson, Minnie M. Wu, Grant R. Budas, David G. Breckenridge, Ewen M. Harrison, Damian J. Mole, Stephen J. Wigmore, Prakash Ramachandran, Chris P. Ponting, Sarah A. Teichmann, John C. Marioni, Neil C. Henderson

Get full text